Biophytis S.A. (BPTSY) - Total Liabilities
Based on the latest financial reports, Biophytis S.A. (BPTSY) has total liabilities worth $15.13 Million USD as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Biophytis S.A. cash flow conversion to assess how effectively this company generates cash.
Biophytis S.A. - Total Liabilities Trend (2012–2023)
This chart illustrates how Biophytis S.A.'s total liabilities have evolved over time, based on quarterly financial data. Check Biophytis S.A. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Biophytis S.A. Competitors by Total Liabilities
The table below lists competitors of Biophytis S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CQS New City High Yield Fund
LSE:NCYF
|
UK | GBX40.64 Million |
|
Zelira Therapeutics Ltd
AU:ZLD
|
Australia | AU$5.59 Million |
|
Austin Metals Ltd
AU:AYT
|
Australia | AU$518.82K |
|
BGT Corporation Public Company Limited
BK:BGT
|
Thailand | ฿348.52 Million |
|
Leveljump Healthcare Corp
V:JUMP
|
Canada | CA$15.49 Million |
|
Crown Energy AB (publ)
F:CWE
|
Germany | €2.77 Billion |
|
Henderson International Income Trust PLC
LSE:HINT
|
UK | GBX40.28 Million |
|
Anagenics Ltd
AU:AN1
|
Australia | AU$1.82 Million |
Liability Composition Analysis (2012–2023)
This chart breaks down Biophytis S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Biophytis S.A. worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biophytis S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biophytis S.A. (2012–2023)
The table below shows the annual total liabilities of Biophytis S.A. from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $15.85 Million | -33.68% |
| 2022-12-31 | $23.90 Million | -21.79% |
| 2021-12-31 | $30.56 Million | +49.95% |
| 2020-12-31 | $20.38 Million | -19.13% |
| 2019-12-31 | $25.20 Million | +69.61% |
| 2018-12-31 | $14.86 Million | +212.04% |
| 2017-12-31 | $4.76 Million | +22.90% |
| 2016-12-31 | $3.87 Million | +109.34% |
| 2015-12-31 | $1.85 Million | +22.09% |
| 2014-12-31 | $1.52 Million | +46.15% |
| 2013-12-31 | $1.04 Million | -4.36% |
| 2012-12-31 | $1.08 Million | -- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, … Read more